Cargando…

Establishing an 8‐gene immune prognostic model based on TP53 status for lung adenocarcinoma

BACKGROUND: Lung adenocarcinoma (LUAD) results in a majority of cancer burden worldwide. TP53 is the most commonly mutated in LUAD. This study aimed to reveal the relation between TP53 and tumor microenvironment (TME) for improving LUAD treatment. METHODS: Differentially expressed genes (DEGs) relat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Guodong, Wang, Youyu, Wan, Yanhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279974/ https://www.ncbi.nlm.nih.gov/pubmed/35689561 http://dx.doi.org/10.1002/jcla.24538

Ejemplares similares

Clinical and prognostic implications of an immune‐related risk model based on TP53 status in lung adenocarcinoma
por: Song, Xuming, et al.
Publicado: (2021)

Immune landscape and a promising immune prognostic model associated with TP53 in early‐stage lung adenocarcinoma
por: Wu, Chengde, et al.
Publicado: (2020)

p53/TP53 Status Assessment in Gastroesophageal Adenocarcinoma
por: Boldrin, Elisa, et al.
Publicado: (2023)

A TP53 Related Immune Prognostic Model for the Prediction of Clinical Outcomes and Therapeutic Responses in Lung Adenocarcinoma
por: Zhang, Xiaonan, et al.
Publicado: (2022)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
por: Sun, Hao, et al.
Publicado: (2020)

Prognostic value of Beclin 1, EGFR and ALK in non-squamous non-small cell lung cancer
por: Wan, Yanhui, et al.
Publicado: (2022)

Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma
por: Feng, Juan, et al.
Publicado: (2023)

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
por: Lin, Xinqing, et al.
Publicado: (2020)

A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with TP53 mutation
por: Fu, Jing, et al.
Publicado: (2021)

Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD‐L1 immunotherapy
por: Wu, Chih‐Hsun, et al.
Publicado: (2019)

Construction and Validation of an Immune-Related Prognostic Model Based on TP53 Status in Colorectal Cancer
por: Zhao, Xiaojuan, et al.
Publicado: (2019)

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
por: Li, He, et al.
Publicado: (2023)

TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer
por: Langerød, Anita, et al.
Publicado: (2007)

Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer
por: Langerød, A, et al.
Publicado: (2005)

TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival
por: Freudenstein, Donald, et al.
Publicado: (2020)

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
por: Schabath, Matthew B., et al.
Publicado: (2015)

Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation
por: Zeng, Dejun, et al.
Publicado: (2021)

Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2015)

Coexisting EGFR and TP53 Mutations in Lung Adenocarcinoma Patients Are Associated With COMP and ITGB8 Upregulation and Poor Prognosis
por: Zheng, Chang, et al.
Publicado: (2020)

Identification of Key Genes in Lung Adenocarcinoma and Establishment of Prognostic Mode
por: Jiawei, Zhou, et al.
Publicado: (2020)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Mesonephric Adenocarcinoma of the Vagina Harboring TP53 Mutation
por: Lee, Hyunjee, et al.
Publicado: (2022)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis
por: Fisher, Oliver M, et al.
Publicado: (2017)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

A case report of low grade fetal lung adenocarcinoma with TP53 mutation
por: Wang, Bo, et al.
Publicado: (2022)

Prognostic Factors of IIIAN2 Non-Small-Cell Lung Cancer after Complete Resection: A Systemic Review and Meta-analysis
por: Wang, Youyu, et al.
Publicado: (2021)

Establishing the Link between X-Chromosome Aberrations and TP53 Status, with Breast Cancer Patient Outcomes
por: Caramia, Franco, et al.
Publicado: (2023)

Significance of TP53 and immune-related genes to prostate cancer
por: Huang, Hang, et al.
Publicado: (2021)

Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms
por: Moore, Ellen C., et al.
Publicado: (2018)

TP53 Gene Status Affects Survival in Advanced Mycosis Fungoides
por: Wooler, Gitte, et al.
Publicado: (2016)

Identification of TP53 mutation-associated prognostic genes and investigation of the immune cell infiltration in patients with hepatocellular carcinoma
por: Yang, Qijun, et al.
Publicado: (2023)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

Establishment of lung adenocarcinoma classification and risk model based on necroptosis-related genes
por: Wu, Guodong, et al.
Publicado: (2022)

Expression and prognostic significance of m6A‐related genes in TP53‐mutant non‐small‐cell lung cancer
por: Zhao, Zhuochen, et al.
Publicado: (2021)

Prognostic significance of TP53 alterations in breast carcinoma.
por: Andersen, T. I., et al.
Publicado: (1993)

Differentiating TP53 Mutation Status in Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI-Derived Radiomics
por: Gao, Jing, et al.
Publicado: (2021)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

LncRNA WT1-AS downregulates lncRNA UCA1 to suppress non-small cell lung cancer and predicts poor survival
por: Wan, Yanhui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r8lj9a6909idtp2qiaeatu469d